4.7 Article

Vaccine-associated paralytic poliomyelitis in the Russian Federation in 1998-2014

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2018.08.017

关键词

Poliomyelitis; VAPP; Poliovirus vaccine; IPV; OPV

资金

  1. Federal Budget of the Russian Federation
  2. WHO Polio Eradication Programme
  3. WHO Regional Office for Europe
  4. Russian Science Foundation [15-15-00147]
  5. Russian academic excellence project 5-100
  6. Russian Science Foundation [15-15-00147] Funding Source: Russian Science Foundation

向作者/读者索取更多资源

Objectives: Different polio vaccination schemes have been used in Russia: oral polio vaccine (OPV) was used in 1998-2007 and inactivated polio vaccine (IPV) followed by OPV in 2008-2014. This article presents the characteristics of vaccine-associated paralytic poliomyelitis (VAPP) cases in Russia during this period. Methods: VAPP cases were identified through the acute flaccid paralysis surveillance system, classified by the National Expert Classification Committee. Criteria for a 'recipient VAPP' (rVAPP) case were poliomyelitis symptoms 6-30 days a(f)ter OPV administration, isolation of the vaccine virus, and residual paralysis 60 days after disease onset. Unvaccinated cases with a similar picture 6-60 days after contact with an OPV recipient were classified as 'contact VAPP' (cVAPP) cases. Results: During 1998-2014, 127 VAPP cases were registered: 82 rVAPP and 45 cVAPP. During the period in which only OPV was used, rVAPP cases prevailed (73.8%); cases of rVAPP were reduced during the sequential scheme period (15%). Poliovirus type 3 (39.5%) and type 2 (23.7%) were isolated more often. Vaccine-derived poliovirus types 1, 2, and 3 were isolated from three cases of cVAPP. The incidence of VAPP cases was higher during the period of OPV use (1 case/1.59 million OPV doses) than during the sequential scheme period (1 case/4.18 million doses). Conclusion: The risk of VAPP exists if OPV remains in the vaccination schedule. (c) 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据